Press Releases

<< Back
Dec 23, 2020

Ziopharm to Participate in Upcoming January Conferences

BOSTON, Dec. 23, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in a fireside chat at the H.C. Wainwright Bioconnect 2021 Conference and will deliver a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference.

H.C. Wainwright Bioconnect 2021 Conference
Date: Monday, January 11, 2021
Time: 6:00 am ET (access to on demand webcast begins)

39th Annual J.P. Morgan Healthcare Conference 
Date: Thursday, January 14, 2021
Time: 8:20 am ET 

To access the webcast presentations, or the subsequent archived recordings, please visit the “Investors” section of the Ziopharm website at

About Ziopharm Oncology, Inc.
Ziopharm is developing non-viral and cytokine-driven cell and gene therapies that weaponize the body’s immune system to treat the millions of people globally diagnosed with a solid tumor each year. With its multiplatform approach, Ziopharm is at the forefront of immuno-oncology with a goal to treat any type of solid tumor. Ziopharm’s pipeline is built for commercially scalable, cost effective T-cell receptor T-cell therapies based on its non-viral Sleeping Beauty gene transfer platform, a precisely controlled IL-12 gene therapy, and rapidly manufactured Sleeping Beauty-enabled CD19-specific CAR-T program. The Company has clinical and strategic partnerships with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and others. For more information, please visit

Investor Relations Contacts:
Adam D. Levy, PhD, MBA
EVP, Investor Relations and Corporate Communications
(508) 552-9255

Media Relations Contact:
LifeSci Communications:
Patrick Bursey
T: 646.876.4932

Primary Logo

Source: ZIOPHARM Oncology Inc